PRO ONCO DUCTS

Acellbia® (rituximab)

Acellbia® (rituximab)

Rituximab biosimilar, chimeric monoclonal antibody which specifically binds to the transmembrane antigen CD20. Indications: non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). Currently >60 000 patients treated, >650 000 vials sold, marketed in 14 countries.
Avegra® (bevacizumab)

Avegra® (bevacizumab)

Bevacizumab biosimilar, recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A). Indications: colorectal cancer, ovarian and cervical cancer, lung cancer, renal cell cancer, glioblastoma, breast cancer. Currently >10 000 patients treated, >332 000 vials sold, marketed in 9 countries.
Herticad® (trastuzumab)

Herticad® (trastuzumab)

Trastuzumab biosimilar, recombinant humanized IgG1 monoclonal antibody against the human epidermal growth factor receptor 2 (HER2) that has been shown to inhibit the proliferation of HER2 overexpressing cancer cells.

anti PD-1 mAb

CDK8 inhibitor

ANTI CTLA4 MAB

anti PD-L1 mAb

anti CD47 mAb

anti CD20 mAb

anti C-MET mAb